BioCentury | Sep 10, 2012
Financial News

Laurantis Pharma completes venture financing

Laurantis Pharma Oy , Turku, Finland Business: Inflammation, Cancer, Dermatology Date completed: 9/4/12 Type: Venture financing Raised: €5.6 million ($7.1 million) Investors: Broadview Ventures; Inveni Capital; Aloitusrahasto Vera; Helsinki University Fund; Veritas WIR Staff...
BioCentury | Jul 9, 2012
Clinical News

Cis-UCA acid eye drops: Phase I data

...eye drops were well tolerated with no local eye irritation or systemic adverse events reported. Laurantis Pharma Oy...
BioCentury | Oct 17, 2011
Clinical News

Laurantis Pharma preclinical data

...start clinical testing of the adenoviral vector expressing VEGF-C to treat secondary lymphedema in 2012. Laurantis Pharma Oy...
BioCentury | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

...BioCis and Lx Therapies merged to form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president...
Items per page:
1 - 4 of 4
BioCentury | Sep 10, 2012
Financial News

Laurantis Pharma completes venture financing

Laurantis Pharma Oy , Turku, Finland Business: Inflammation, Cancer, Dermatology Date completed: 9/4/12 Type: Venture financing Raised: €5.6 million ($7.1 million) Investors: Broadview Ventures; Inveni Capital; Aloitusrahasto Vera; Helsinki University Fund; Veritas WIR Staff...
BioCentury | Jul 9, 2012
Clinical News

Cis-UCA acid eye drops: Phase I data

...eye drops were well tolerated with no local eye irritation or systemic adverse events reported. Laurantis Pharma Oy...
BioCentury | Oct 17, 2011
Clinical News

Laurantis Pharma preclinical data

...start clinical testing of the adenoviral vector expressing VEGF-C to treat secondary lymphedema in 2012. Laurantis Pharma Oy...
BioCentury | Jun 13, 2011
Company News

BioCis Pharma Ltd., Lx Therapies deal

...BioCis and Lx Therapies merged to form Laurantis Pharma Oy . The newco hired Riku Rautsola, former president...
Items per page:
1 - 4 of 4